Effects of multistrain Bifidobacteria and Lactobacillus probiotics on HMO compositions after supplementation to pregnant women at threatening preterm delivery: design of the randomized clinical PROMO trial.
Bifidobacteria
Entero-mammary pathway
Human milk oligosaccharides
Microbiome
Preterm birth
Probiotics
Journal
Molecular and cellular pediatrics
ISSN: 2194-7791
Titre abrégé: Mol Cell Pediatr
Pays: Germany
ID NLM: 101660689
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
05
04
2024
accepted:
22
07
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
As an indigestible component of human breast milk, Human Milk Oligosaccharides (HMOs) play an important role as a substrate for the establishing microbiome of the newborn. They have further been shown to have beneficial effects on the immune system, lung and brain development. For preterm infants HMO composition of human breast milk may be of particular relevance since the establishment of a healthy microbiome is challenged by multiple disruptive factors associated with preterm birth, such as cesarean section, hospital environment and perinatal antibiotic exposure. In a previous study it has been proposed that maternal probiotic supplementation during late stages of pregnancy may change the HMO composition in human milk. However, there is currently no study on pregnancies which are threatened to preterm birth. Furthermore, HMO composition has not been investigated in association with clinically relevant outcomes of vulnerable infants including inflammation-mediated diseases such as sepsis, necrotizing enterocolitis (NEC) or chronic lung disease. A randomized controlled intervention study (PROMO = probiotics for human milk oligosaccharides) has been designed to analyze changes in HMO composition of human breast milk after supplementation of probiotics (Lactobacillus acidophilus, Bifidobacterium lactis and Bifidobacterium infantis) in pregnancies at risk for preterm birth. The primary endpoint is HMO composition of 3-fucosyllactose and 3'-sialyllactose in expressed breast milk. We estimate that probiotic intervention will increase these two HMO levels by 50% according to the standardized mean difference between treatment and control groups. As secondary outcomes we will measure preterm infants' clinical outcomes (preterm birth, sepsis, weight gain growth, gastrointestinal complications) and effects on microbiome composition in the rectovaginal tract of mothers at delivery and in the gut of term and preterm infants by sequencing at high genomic resolution. Therefore, we will longitudinally collect bio samples in the first 4 weeks after birth as well as in follow-up investigations at 3 months, one year, and five years of age. We estimate that probiotic intervention will increase these two HMO levels by 50% according to the standardized mean difference between treatment and control groups. The PROMO study will gain insight into the microbiome-HMO interaction at the fetomaternal interface and its consequences for duration of pregnancy and outcome of infants.
Sections du résumé
BACKGROUND
BACKGROUND
As an indigestible component of human breast milk, Human Milk Oligosaccharides (HMOs) play an important role as a substrate for the establishing microbiome of the newborn. They have further been shown to have beneficial effects on the immune system, lung and brain development. For preterm infants HMO composition of human breast milk may be of particular relevance since the establishment of a healthy microbiome is challenged by multiple disruptive factors associated with preterm birth, such as cesarean section, hospital environment and perinatal antibiotic exposure. In a previous study it has been proposed that maternal probiotic supplementation during late stages of pregnancy may change the HMO composition in human milk. However, there is currently no study on pregnancies which are threatened to preterm birth. Furthermore, HMO composition has not been investigated in association with clinically relevant outcomes of vulnerable infants including inflammation-mediated diseases such as sepsis, necrotizing enterocolitis (NEC) or chronic lung disease.
MAIN BODY
METHODS
A randomized controlled intervention study (PROMO = probiotics for human milk oligosaccharides) has been designed to analyze changes in HMO composition of human breast milk after supplementation of probiotics (Lactobacillus acidophilus, Bifidobacterium lactis and Bifidobacterium infantis) in pregnancies at risk for preterm birth. The primary endpoint is HMO composition of 3-fucosyllactose and 3'-sialyllactose in expressed breast milk. We estimate that probiotic intervention will increase these two HMO levels by 50% according to the standardized mean difference between treatment and control groups. As secondary outcomes we will measure preterm infants' clinical outcomes (preterm birth, sepsis, weight gain growth, gastrointestinal complications) and effects on microbiome composition in the rectovaginal tract of mothers at delivery and in the gut of term and preterm infants by sequencing at high genomic resolution. Therefore, we will longitudinally collect bio samples in the first 4 weeks after birth as well as in follow-up investigations at 3 months, one year, and five years of age.
CONCLUSIONS
CONCLUSIONS
We estimate that probiotic intervention will increase these two HMO levels by 50% according to the standardized mean difference between treatment and control groups. The PROMO study will gain insight into the microbiome-HMO interaction at the fetomaternal interface and its consequences for duration of pregnancy and outcome of infants.
Identifiants
pubmed: 39085734
doi: 10.1186/s40348-024-00179-5
pii: 10.1186/s40348-024-00179-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
6Informations de copyright
© 2024. The Author(s).
Références
Seppo AE, Kukkonen AK, Kuitunen M, Savilahti E, Yonemitsu C, Bode L, Järvinen KM (2019) Association of Maternal Probiotic Supplementation with Human Milk Oligosaccharide Composition. JAMA Pediatr 173:286–288. https://doi.org/10.1001/jamapediatrics.2018.4835
doi: 10.1001/jamapediatrics.2018.4835
pubmed: 30667484
pmcid: 6439880
Urashima T, Fukuda K, Messer M (2012) Evolution of milk oligosaccharides and lactose: a hypothesis. Animal 6:369–374. https://doi.org/10.1017/S1751731111001248
doi: 10.1017/S1751731111001248
pubmed: 22436215
Stahl B, Thurl S, Zeng J, Karas M, Hillenkamp F, Steup M, Sawatzki G (1994) Oligosaccharides from human milk as revealed by matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 223:218–226. https://doi.org/10.1006/abio.1994.1577
doi: 10.1006/abio.1994.1577
pubmed: 7887467
Soyyılmaz B, Mikš MH, Röhrig CH, Matwiejuk M, Meszaros-Matwiejuk A, Vigsnæs LK (2021) The Mean of milk: a review of human milk oligosaccharide concentrations throughout Lactation. Nutrients 13:2737. https://doi.org/10.3390/nu13082737
doi: 10.3390/nu13082737
pubmed: 34444897
pmcid: 8398195
Bode L (2012) Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology 22:1147–1162. https://doi.org/10.1093/glycob/cws074
doi: 10.1093/glycob/cws074
pubmed: 22513036
pmcid: 3406618
Azad MB, Robertson B, Atakora F, Becker AB, Subbarao P, Moraes TJ, Mandhane PJ, Turvey SE, Lefebvre DL, Sears MR, Bode L (2018) Human Milk Oligosaccharide Concentrations Are Associated with multiple fixed and modifiable maternal characteristics, Environmental Factors, and feeding practices. J Nutr 148:1733–1742. https://doi.org/10.1093/jn/nxy175
doi: 10.1093/jn/nxy175
pubmed: 30247646
Cabrera-Rubio R, Kunz C, Rudloff S, García-Mantrana I, Crehuá-Gaudiza E, Martínez-Costa C, Collado MC (2019) Association of maternal secretor status and human milk oligosaccharides with milk microbiota: an Observational Pilot Study. J Pediatr Gastroenterol Nutr 68:256–263. https://doi.org/10.1097/MPG.0000000000002216
doi: 10.1097/MPG.0000000000002216
pubmed: 30540710
Gabrielli O, Zampini L, Galeazzi T, Padella L, Santoro L, Peila C, Giuliani F, Bertino E, Fabris C, Coppa GV (2011) Preterm milk oligosaccharides during the first month of lactation. Pediatrics 128:e1520–1531. https://doi.org/10.1542/peds.2011-1206
doi: 10.1542/peds.2011-1206
pubmed: 22123889
Kunz C, Rudloff S, Baier W, Klein N, Strobel S (2000) Oligosaccharides in human milk: structural, functional, and metabolic aspects. Annu Rev Nutr 20:699–722. https://doi.org/10.1146/annurev.nutr.20.1.699
doi: 10.1146/annurev.nutr.20.1.699
pubmed: 10940350
Blank D, Dotz V, Geyer R, Kunz C (2012) Human milk oligosaccharides and Lewis blood group: individual high-throughput sample profiling to enhance conclusions from functional studies. Adv Nutr 3:440S–9S. https://doi.org/10.3945/an.111.001446
doi: 10.3945/an.111.001446
pubmed: 22585923
pmcid: 3649481
Sprenger N, Lee LY, De Castro CA, Steenhout P, Thakkar SK (2017) Longitudinal change of selected human milk oligosaccharides and association to infants’ growth, an observatory, single center, longitudinal cohort study. PLoS ONE 12:e0171814. https://doi.org/10.1371/journal.pone.0171814
doi: 10.1371/journal.pone.0171814
pubmed: 28182762
pmcid: 5300226
Akkerman R, Faas MM, de Vos P (2019) Non-digestible carbohydrates in infant formula as substitution for human milk oligosaccharide functions: effects on microbiota and gut maturation. Crit Rev Food Sci Nutr 59:1486–1497. https://doi.org/10.1080/10408398.2017.1414030
doi: 10.1080/10408398.2017.1414030
pubmed: 29333864
Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, Belzer C, Delgado Palacio S, Arboleya Montes S, Mancabelli L, Lugli GA, Rodriguez JM, Bode L, de Vos W, Gueimonde M, Margolles A, van Sinderen D, Ventura M (2017) The First Microbial colonizers of the human gut: composition, activities, and Health implications of the infant gut microbiota. Microbiol Mol Biol Rev 81:e00036–e00017. https://doi.org/10.1128/MMBR.00036-17
doi: 10.1128/MMBR.00036-17
pubmed: 29118049
pmcid: 5706746
Rousseaux A, Brosseau C, Le Gall S, Piloquet H, Barbarot S, Bodinier M (2021) Human milk oligosaccharides: their effects on the host and their potential as therapeutic agents. Front Immunol 12:680911. https://doi.org/10.3389/fimmu.2021.680911
doi: 10.3389/fimmu.2021.680911
pubmed: 34108974
pmcid: 8180913
Corona L, Lussu A, Bosco A, Pintus R, Cesare Marincola F, Fanos V, Dessì A (2021) Human milk oligosaccharides: a Comprehensive Review towards Metabolomics. Child (Basel) 8:804. https://doi.org/10.3390/children8090804
doi: 10.3390/children8090804
Tarr AJ, Galley JD, Fisher SE, Chichlowski M, Berg BM, Bailey MT (2015) The prebiotics 3’sialyllactose and 6’sialyllactose diminish stressor-induced anxiety-like behavior and colonic microbiota alterations: evidence for effects on the gut-brain axis. Brain Behav Immun 50:166–177. https://doi.org/10.1016/j.bbi.2015.06.025
doi: 10.1016/j.bbi.2015.06.025
pubmed: 26144888
pmcid: 4631662
Ward RE, Niñonuevo M, Mills DA, Lebrilla CB, German JB (2007) In vitro fermentability of human milk oligosaccharides by several strains of bifidobacteria. Mol Nutr Food Res 51:1398–1405. https://doi.org/10.1002/mnfr.200700150
doi: 10.1002/mnfr.200700150
pubmed: 17966141
Locascio RG, Niñonuevo MR, Kronewitter SR, Freeman SL, German JB, Lebrilla CB, Mills DA (2009) A versatile and scalable strategy for glycoprofiling bifidobacterial consumption of human milk oligosaccharides. Microb Biotechnol 2:333–342. https://doi.org/10.1111/j.1751-7915.2008.00072.x
doi: 10.1111/j.1751-7915.2008.00072.x
pubmed: 21261928
pmcid: 3815754
Ruiz-Moyano S, Totten SM, Garrido DA, Smilowitz JT, German JB, Lebrilla CB, Mills DA (2013) Variation in consumption of human milk oligosaccharides by infant gut-associated strains of Bifidobacterium breve. Appl Environ Microbiol 79:6040–6049. https://doi.org/10.1128/AEM.01843-13
doi: 10.1128/AEM.01843-13
pubmed: 23892749
pmcid: 3811376
Yu Z-T, Chen C, Newburg DS (2013) Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. Glycobiology 23:1281–1292. https://doi.org/10.1093/glycob/cwt065
doi: 10.1093/glycob/cwt065
pubmed: 24013960
pmcid: 3796377
Duijts L, Jaddoe VWV, Hofman A, Moll HA (2010) Prolonged and exclusive breastfeeding reduces the risk of infectious diseases in infancy. Pediatrics 126:e18–25. https://doi.org/10.1542/peds.2008-3256
doi: 10.1542/peds.2008-3256
pubmed: 20566605
Cheng Y-J, Yeung C-Y (2021) Recent advance in infant nutrition: human milk oligosaccharides. Pediatr Neonatol 62:347–353. https://doi.org/10.1016/j.pedneo.2020.12.013
doi: 10.1016/j.pedneo.2020.12.013
pubmed: 33893051
Zuurveld M, Ayechu-Muruzabal V, Folkerts G, Garssen J, van‘t Land B, Willemsen LEM (2023) Specific Human Milk Oligosaccharides differentially promote Th1 and Regulatory responses in a CpG-Activated Epithelial/Immune cell coculture. Biomolecules 13:263. https://doi.org/10.3390/biom13020263
doi: 10.3390/biom13020263
pubmed: 36830632
pmcid: 9953370
Underwood MA, Gaerlan S, De Leoz MLA, Dimapasoc L, Kalanetra KM, Lemay DG, German JB, Mills DA, Lebrilla CB (2015) Human milk oligosaccharides in premature infants: absorption, excretion, and influence on the intestinal microbiota. Pediatr Res 78:670–677. https://doi.org/10.1038/pr.2015.162
doi: 10.1038/pr.2015.162
pubmed: 26322410
pmcid: 4689671
Moukarzel S, Bode L (2017) Human milk oligosaccharides and the Preterm Infant: a journey in sickness and in Health. Clin Perinatol 44:193–207. https://doi.org/10.1016/j.clp.2016.11.014
doi: 10.1016/j.clp.2016.11.014
pubmed: 28159206
Autran CA, Kellman BP, Kim JH, Asztalos E, Blood AB, Spence ECH, Patel AL, Hou J, Lewis NE, Bode L (2018) Human milk oligosaccharide composition predicts risk of necrotising enterocolitis in preterm infants. Gut 67:1064–1070. https://doi.org/10.1136/gutjnl-2016-312819
doi: 10.1136/gutjnl-2016-312819
pubmed: 28381523
Masi AC, Embleton ND, Lamb CA, Young G, Granger CL, Najera J, Smith DP, Hoffman KL, Petrosino JF, Bode L, Berrington JE, Stewart CJ (2021) Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis. Gut 70:2273–2282. https://doi.org/10.1136/gutjnl-2020-322771
doi: 10.1136/gutjnl-2020-322771
pubmed: 33328245
Humberg A, Fortmann I, Siller B, Kopp MV, Herting E, Göpel W, Härtel C, German Neonatal Network, German Center for Lung Research and Priming Immunity at the beginning of life (PRIMAL) Consortium (2020) Preterm birth and sustained inflammation: consequences for the neonate. Semin Immunopathol 42:451–468. https://doi.org/10.1007/s00281-020-00803-2
doi: 10.1007/s00281-020-00803-2
pubmed: 32661735
pmcid: 7508934
Graspeuntner S, Waschina S, Künzel S, Twisselmann N, Rausch TK, Cloppenborg-Schmidt K, Zimmermann J, Viemann D, Herting E, Göpel W, Baines JF, Kaleta C, Rupp J, Härtel C, Pagel J (2019) Gut dysbiosis with Bacilli Dominance and Accumulation of Fermentation products precedes late-onset Sepsis in Preterm infants. Clin Infect Dis 69:268–277. https://doi.org/10.1093/cid/ciy882
doi: 10.1093/cid/ciy882
pubmed: 30329017
Halkjær SI, de Knegt VE, Lo B, Nilas L, Cortes D, Pedersen AE, Mirsepasi-Lauridsen HC, Andersen LO, Nielsen HV, Stensvold CR, Johannesen TB, Kallemose T, Krogfelt KA, Petersen AM (2020) Multistrain Probiotic increases the gut microbiota diversity in obese pregnant women: results from a Randomized, double-blind placebo-controlled study. Curr Dev Nutr 4:nzaa095. https://doi.org/10.1093/cdn/nzaa095
doi: 10.1093/cdn/nzaa095
pubmed: 32617453
pmcid: 7319727
Luoto R, Laitinen K, Nermes M, Isolauri E (2010) Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br J Nutr 103:1792–1799. https://doi.org/10.1017/S0007114509993898
doi: 10.1017/S0007114509993898
pubmed: 20128938
Vitali B, Cruciani F, Baldassarre ME, Capursi T, Spisni E, Valerii MC, Candela M, Turroni S, Brigidi P (2012) Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion. BMC Microbiol 12:236. https://doi.org/10.1186/1471-2180-12-236
doi: 10.1186/1471-2180-12-236
pubmed: 23078375
pmcid: 3493352
Badehnoosh B, Karamali M, Zarrati M, Jamilian M, Bahmani F, Tajabadi-Ebrahimi M, Jafari P, Rahmani E, Asemi Z (2018) The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med 31:1128–1136. https://doi.org/10.1080/14767058.2017.1310193
doi: 10.1080/14767058.2017.1310193
pubmed: 28326881
Dewanto NEF, Firmansyah A, Sungkar A, Dharmasetiawani N, Sastroasmoro S, Kresno SB, Suradi R, Bardosono S, Prasetyo D (2017) The effect of bifidobacterium animalis lactis HNO19 supplementation among pregnant and lactating women on interleukin-8 level in breast milk and infant’s gut mucosal integrity. Med J Indonesia 26:204–211. https://doi.org/10.13181/mji.v26i3.1481
doi: 10.13181/mji.v26i3.1481
Mastromarino P, Capobianco D, Miccheli A, Praticò G, Campagna G, Laforgia N, Capursi T, Baldassarre ME (2015) Administration of a multistrain probiotic product (VSL#3) to women in the perinatal period differentially affects breast milk beneficial microbiota in relation to mode of delivery. Pharmacol Res 95–96:63–70. https://doi.org/10.1016/j.phrs.2015.03.013
doi: 10.1016/j.phrs.2015.03.013
pubmed: 25836922
Yang S, Reid G, Challis JRG, Gloor GB, Asztalos E, Money D, Seney S, Bocking AD (2020) Effect of oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the vaginal microbiota, cytokines and chemokines in pregnant women. Nutrients 12:368. https://doi.org/10.3390/nu12020368
doi: 10.3390/nu12020368
pubmed: 32019222
pmcid: 7071157
Ho M, Chang Y-Y, Chang W-C, Lin H-C, Wang M-H, Lin W-C, Chiu T-H (2016) Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: a randomized controlled trial. Taiwan J Obstet Gynecol 55:515–518. https://doi.org/10.1016/j.tjog.2016.06.003
doi: 10.1016/j.tjog.2016.06.003
pubmed: 27590374
Ang X-Y, Roslan NS, Ahmad N, Yusof SM, Abdullah N, Rahman NNNA, Woon J-J, Teh CS-J, Todorov SD, Liu G, Liong M-T (2023) Lactobacillus probiotics restore vaginal and gut microbiota of pregnant women with vaginal candidiasis. Beneficial Microbes 14:421–431. https://doi.org/10.1163/18762891-20220103
doi: 10.1163/18762891-20220103
pubmed: 38350486
Dotterud CK, Avershina E, Sekelja M, Simpson MR, Rudi K, Storrø O, Johnsen R, Øien T (2015) Does maternal perinatal probiotic supplementation alter the intestinal microbiota of mother and child? J Pediatr Gastroenterol Nutr 61:200–207. https://doi.org/10.1097/MPG.0000000000000781
doi: 10.1097/MPG.0000000000000781
pubmed: 25782657
Enomoto T, Sowa M, Nishimori K, Shimazu S, Yoshida A, Yamada K, Furukawa F, Nakagawa T, Yanagisawa N, Iwabuchi N, Odamaki T, Abe F, Nakayama J, Xiao J-Z (2014) Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int 63:575–585. https://doi.org/10.2332/allergolint.13-OA-0683
doi: 10.2332/allergolint.13-OA-0683
pubmed: 25056226
Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor MB, Garaiova I, Plummer SF, Wang D, Morgan G (2014) Probiotics in the prevention of eczema: a randomised controlled trial. Arch Dis Child 99:1014–1019. https://doi.org/10.1136/archdischild-2013-305799
doi: 10.1136/archdischild-2013-305799
pubmed: 24947281
Rodríguez JM, Fernández L, Verhasselt V (2021) The gut–breast Axis: Programming Health for Life. Nutrients 13:606. https://doi.org/10.3390/nu13020606
doi: 10.3390/nu13020606
pubmed: 33673254
pmcid: 7917897
Bering SB (2018) Human milk oligosaccharides to prevent gut dysfunction and necrotizing enterocolitis in Preterm neonates. Nutrients 10:1461. https://doi.org/10.3390/nu10101461
doi: 10.3390/nu10101461
pubmed: 30297668
pmcid: 6213229
Gavzy SJ, Kensiski A, Lee ZL, Mongodin EF, Ma B, Bromberg JS (2023) Bifidobacterium mechanisms of immune modulation and tolerance. Gut Microbes 15:2291164. https://doi.org/10.1080/19490976.2023.2291164
doi: 10.1080/19490976.2023.2291164
pubmed: 38055306
pmcid: 10730214
Morrison DJ, Preston T (2016) Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 7:189–200. https://doi.org/10.1080/19490976.2015.1134082
doi: 10.1080/19490976.2015.1134082
pubmed: 26963409
pmcid: 4939913
Chang PV, Hao L, Offermanns S, Medzhitov R (2014) The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A 111:2247–2252. https://doi.org/10.1073/pnas.1322269111
doi: 10.1073/pnas.1322269111
pubmed: 24390544
pmcid: 3926023
Al-Khafaji AH, Jepsen SD, Christensen KR, Vigsnæs LK (2020) The potential of human milk oligosaccharides to impact the microbiota-gut-brain axis through modulation of the gut microbiota. J Funct Foods 74:104176. https://doi.org/10.1016/j.jff.2020.104176
doi: 10.1016/j.jff.2020.104176
Cho S, Zhu Z, Li T, Baluyot K, Howell BR, Hazlett HC, Elison JT, Hauser J, Sprenger N, Wu D, Lin W (2021) Human milk 3’-Sialyllactose is positively associated with language development during infancy. Am J Clin Nutr 114:588–597. https://doi.org/10.1093/ajcn/nqab103
doi: 10.1093/ajcn/nqab103
pubmed: 34020453
pmcid: 8326052
Dinleyici M, Barbieur J, Dinleyici EC, Vandenplas Y (2023) Functional effects of human milk oligosaccharides (HMOs). Gut Microbes 15:2186115. https://doi.org/10.1080/19490976.2023.2186115
doi: 10.1080/19490976.2023.2186115
pubmed: 36929926
pmcid: 10026937
Berger PK, Plows JF, Jones RB, Alderete TL, Yonemitsu C, Poulsen M, Ryoo JH, Peterson BS, Bode L, Goran MI (2020) Human milk oligosaccharide 2’-fucosyllactose links feedings at 1 month to cognitive development at 24 months in infants of normal and overweight mothers. PLoS ONE 15:e0228323. https://doi.org/10.1371/journal.pone.0228323
doi: 10.1371/journal.pone.0228323
pubmed: 32049968
pmcid: 7015316
Härtel C, Pagel J, Rupp J, Bendiks M, Guthmann F, Rieger-Fackeldey E, Heckmann M, Franz A, Schiffmann J-H, Zimmermann B, Hepping N, von der Wense A, Wieg C, Herting E, Göpel W, German Neonatal Network (2014) Prophylactic use of Lactobacillus acidophilus/Bifidobacterium infantis probiotics and outcome in very low birth weight infants. J Pediatr 165:285–289e1. https://doi.org/10.1016/j.jpeds.2014.04.029
doi: 10.1016/j.jpeds.2014.04.029
pubmed: 24880888
Marißen J, Haiß A, Meyer C, Van Rossum T, Bünte LM, Frommhold D, Gille C, Goedicke-Fritz S, Göpel W, Hudalla H, Pagel J, Pirr S, Siller B, Viemann D, Vens M, König I, Herting E, Zemlin M, Gehring S, Bork P, Henneke P, Härtel C, PRIMAL consortium (2019) Efficacy of Bifidobacterium longum, B. infantis and Lactobacillus acidophilus probiotics to prevent gut dysbiosis in preterm infants of 28 + 0–32 + 6 weeks of gestation: a randomised, placebo-controlled, double-blind, multicentre trial: the PRIMAL clinical study protocol. BMJ Open 9:e032617. https://doi.org/10.1136/bmjopen-2019-032617
doi: 10.1136/bmjopen-2019-032617
pubmed: 31753895
pmcid: 6886923
Fortmann I, Dammann M-T, Siller B, Humberg A, Demmert M, Tüshaus L, Lindert J, van Zandbergen V, Pagel J, Rupp J, Herting E, Härtel C (2021) Infants younger than 90 days admitted for late-onset Sepsis Display a Reduced Abundance of Regulatory T Cells. Front Immunol 12:666447. https://doi.org/10.3389/fimmu.2021.666447
doi: 10.3389/fimmu.2021.666447
pubmed: 34512621
pmcid: 8430331
Wang A, Koleva P, du Toit E, Geddes DT, Munblit D, Prescott SL, Eggesbø M, Johnson CC, Wegienka G, Shimojo N, Campbell D, Kozyrskyj AL, Slupsky CM (2020) The milk metabolome of non-secretor and Lewis Negative Mothers. Front Nutr 7:576966. https://doi.org/10.3389/fnut.2020.576966
doi: 10.3389/fnut.2020.576966
pubmed: 33634158
Kortesniemi M, Jafari T, Zhang Y, Yang B (2022) 1H NMR metabolomics of Chinese Human Milk at Different Stages of Lactation among secretors and non-secretors. Molecules 27:5526. https://doi.org/10.3390/molecules27175526
doi: 10.3390/molecules27175526
pubmed: 36080292
pmcid: 9458218
Pagel J, Twisselmann N, Rausch TK, Waschina S, Hartz A, Steinbeis M, Olbertz J, Nagel K, Steinmetz A, Faust K, Demmert M, Göpel W, Herting E, Rupp J, Härtel C (2020) Increased Regulatory T Cells Precede the Development of Bronchopulmonary Dysplasia in Preterm infants. Front Immunol 11:565257. https://doi.org/10.3389/fimmu.2020.565257
doi: 10.3389/fimmu.2020.565257
pubmed: 33101284
pmcid: 7554370
Pacheco AR, Barile D, Underwood MA, Mills DA (2015) The impact of the milk glycobiome on the neonate gut microbiota. Annu Rev Anim Biosci 3:419–445. https://doi.org/10.1146/annurev-animal-022114-111112
doi: 10.1146/annurev-animal-022114-111112
pubmed: 25387230
Li M, Bai Y, Zhou J, Huang W, Yan J, Tao J, Fan Q, Liu Y, Mei D, Yan Q, Yuan J, Malard P, Wang Z, Gu J, Tanigchi N, Li W (2019) Core fucosylation of maternal milk N-Glycan evokes B Cell activation by selectively promoting the l-Fucose metabolism of gut Bifidobacterium spp. and Lactobacillus spp. mBio 10:e00128–e00119. https://doi.org/10.1128/mBio.00128-19
doi: 10.1128/mBio.00128-19
pubmed: 30940702
pmcid: 6445936
Ansari F, Neshat M, Pourjafar H, Jafari SM, Samakkhah SA, Mirzakhani E (2023) The role of probiotics and prebiotics in modulating of the gut-brain axis. Front Nutr 10:1173660. https://doi.org/10.3389/fnut.2023.1173660
doi: 10.3389/fnut.2023.1173660
pubmed: 37565035
pmcid: 10410452
Zunga M, Yebra MJ, Monedero V (2021) Complex Oligosaccharide Utilization Pathways in Lactobacillus. Curr Issues Mol Biol 40:49–80. https://doi.org/10.21775/cimb.040.049 .
Thongaram T, Hoeflinger JL, Chow J, Miller MJ (2017) Human milk oligosaccharide consumption by probiotic and human-associated bifidobacteria and lactobacilli. J Dairy Sci 100(10):7825–7833. https://doi.org/10.3168/jds.2017-12753
Rodríguez-Díaz J, Monedero V, Yebra MJ (2011) Utilization of Natural Fucosylated Oligosaccharides by Three Novel α-l-Fucosidases from a Probiotic Lactobacillus casei Strain. Appl Environ Microbiol 77(2):703–705. https://doi.org/10.1128/AEM.01906-10